Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AR201
- Development stage
- Discontinued
- Lead developer
- Aimmune Therapeutics
- Modality
- Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
AR201 is an investigational oral immunotherapy developed by Aimmune Therapeutics (a subsidiary of Nestle Health Science) for the treatment of hen egg allergy. It is based on the Characterised Oral Desensitisation ImmunoTherapy (CODIT) platform, which involves desensitizing patients with defined amounts of key allergens to provide protection against allergic reactions. The therapy was designed as a standardized regimen using dried egg white protein to induce desensitization in individuals with egg allergies. The drug reached Phase II clinical trials but development has since been discontinued[1][3][4][7].
- Other names
- AR 201 - food allergy OIT - Aimmune TherapeuticsAR201 - food allergy OIT - Aimmune TherapeuticsAR-201 - food allergy OIT - Aimmune TherapeuticsAR 201 - food allergy oral immunotherapies - Aimmune TherapeuticsAR201 - food allergy oral immunotherapies - Aimmune TherapeuticsAR-201 - food allergy oral immunotherapies - Aimmune TherapeuticsEgg allergy immunotherapy - Aimmune Therapeutics
Beyond the preview
Go deeper on AR201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AR201.